Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome

Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome - Effect of diquafosol sodium and rebamipide on GVHD and Sjogrens syndrome related dry eye.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013234

Enrollment

Registered

2014-04-01

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye related to chronic GVHD and Sjogren s syndrome

Interventions

Diquafosol sodium and rebamipide ophthalmic solution Artifical tears, vitamin A ophthalmic solution, or/and sodium hyaluronate ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Newly-diagnosed dry eye patients after hematopoietic stem cell transplantation 2, Dry eye patients with Sjogren's syndrome 3, Dry eye patients according to the criteria of dry eye (2006 Japanese Dry Eye society)

Exclusion criteria

Exclusion criteria: 1, Dry eye syndrome severity level 4 (dry eye workshop classification 2007) 2, Patients dosed diquafosol sodium and / or rebamipide ophthalmic solution 3, Patients having a concern of becoming severe dry eye because of having GVHD in other organs and so on 4, Patients with ocular pemphigoid, and Stevens-Johnson syndrome 5, Patients with a history of ophthalmic surgery within 6 months before the study 6, Patients wearing contact lens 7, Patients who will be applied radiation treatment during the study 8, Patients dosed cevimeline hydrochloride hydrate and /or pilocarpine(eye drop or oral drug) 9, Patients who will be ineligible for registration the study

Design outcomes

Primary

Measure	Time frame
Anterior ocular segment remark Corneal sensitivity Schirmer test Tear film breakup time Fluorescein staining Rose bengal staining Subjective symptom	—

Countries

Japan

Contacts

Public ContactYoko Ogawa

Keio University School of Medicine Department of Ophthalmology

yoko@z7.keio.jp0353633972

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026